![Rüdiger Horst Robert Ridder](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Rüdiger Horst Robert Ridder
Geen lopende functies
Profiel
Rüdiger Horst Robert Ridder is the founder of mtm laboratories AG, which was founded in 1999.
He held the title of Chief Scientific Officer from 2011 to 2013.
He also held former positions as Co-Managing Director at Signature Diagnostics AG, Project Leader at Henkel AG & Co. KGaA and Novartis Pharmaceuticals UK Ltd., and Principal at Ruprecht-Karls-Universität Heidelberg.
Ridder earned a doctorate degree from Ruhr-Universität Bochum.
Eerdere bekende functies van Rüdiger Horst Robert Ridder
Bedrijven | Functie | Einde |
---|---|---|
mtm laboratories AG
![]() mtm laboratories AG Medical SpecialtiesHealth Technology mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec® Histology kit and CINtec® Cytology kit as adjunct tools for the early detection and diagnosis of cervical cancer. These kits are based on mtm's proprietary E6H4™ antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results. mtm laboratories AG also has programs to identify and develop biomarker based diagnostics for other cancer indications. With its extensive and ever increasing network of clinical research institutions, academic research organizations, and medical professionals active in the field of oncology and molecular pathology, mtm has established a rapid, integrated process for the successful identification and clinical validation of molecular markers associated with cancer. | Oprichter | 02-12-2013 |
Signature Diagnostics AG
![]() Signature Diagnostics AG Pharmaceuticals: MajorHealth Technology Signature Diagnostics AG operates as a molecular diagnostics company. It discovers, validates and develops novel diagnostic products that predict outcome and drug response in patients with colorectal cancer, non-small cell lung cancer and ovarian cancer. The company was founded by André Rosenthal in 2004 and is headquartered in Potsdam, Germany. | Algemeen Directeur | - |
Ruprecht-Karls-Universität Heidelberg | Corporate Officer/Principal | - |
Novartis Pharmaceuticals UK Ltd.
![]() Novartis Pharmaceuticals UK Ltd. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals UK Ltd. manufactures medicines and drugs. The company is headquartered in Camberley, the United kingdom. | Corporate Officer/Principal | - |
HENKEL AG & CO. KGAA | Corporate Officer/Principal | - |
Opleiding van Rüdiger Horst Robert Ridder
Ruhr-Universität Bochum | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
HENKEL AG & CO. KGAA | Consumer Non-Durables |
Bedrijven in privébezit | 3 |
---|---|
mtm laboratories AG
![]() mtm laboratories AG Medical SpecialtiesHealth Technology mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec® Histology kit and CINtec® Cytology kit as adjunct tools for the early detection and diagnosis of cervical cancer. These kits are based on mtm's proprietary E6H4™ antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results. mtm laboratories AG also has programs to identify and develop biomarker based diagnostics for other cancer indications. With its extensive and ever increasing network of clinical research institutions, academic research organizations, and medical professionals active in the field of oncology and molecular pathology, mtm has established a rapid, integrated process for the successful identification and clinical validation of molecular markers associated with cancer. | Health Technology |
Novartis Pharmaceuticals UK Ltd.
![]() Novartis Pharmaceuticals UK Ltd. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals UK Ltd. manufactures medicines and drugs. The company is headquartered in Camberley, the United kingdom. | Health Technology |
Signature Diagnostics AG
![]() Signature Diagnostics AG Pharmaceuticals: MajorHealth Technology Signature Diagnostics AG operates as a molecular diagnostics company. It discovers, validates and develops novel diagnostic products that predict outcome and drug response in patients with colorectal cancer, non-small cell lung cancer and ovarian cancer. The company was founded by André Rosenthal in 2004 and is headquartered in Potsdam, Germany. | Health Technology |